Targeting specific proteins to overcome resistance in melanoma treatment
Combating melanoma resistance by targeting ABL1/2
['FUNDING_R01'] · UNIVERSITY OF KENTUCKY · NIH-11066459
This study is looking at how melanoma cells become resistant to treatments and is testing a leukemia drug called nilotinib to see if it can help patients with advanced melanoma who haven't had success with other therapies.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF KENTUCKY (nih funded) |
| Locations | 1 site (LEXINGTON, UNITED STATES) |
| Trial ID | NIH-11066459 on ClinicalTrials.gov |
What this research studies
This research investigates how melanoma cells develop resistance to current therapies and explores a new approach to overcome this challenge. By focusing on the ABL1 and ABL2 proteins, which become more active when resistance occurs, the study aims to use an existing leukemia drug, nilotinib, to reverse this resistance. The researchers will conduct experiments to understand the mechanisms behind this resistance and test the effectiveness of nilotinib in combination with other treatments. The ultimate goal is to improve survival rates for patients with advanced melanoma who have not responded to standard therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with advanced melanoma who have developed resistance to BRAF and MEK inhibitors.
Not a fit: Patients with early-stage melanoma or those who have not received BRAF or MEK inhibitors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and increased survival rates for patients with metastatic melanoma.
How similar studies have performed: Previous research has shown promise in targeting similar pathways to overcome treatment resistance in cancer, indicating potential for success in this approach.
Where this research is happening
LEXINGTON, UNITED STATES
- UNIVERSITY OF KENTUCKY — LEXINGTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: PLATTNER, RINA — UNIVERSITY OF KENTUCKY
- Study coordinator: PLATTNER, RINA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: advanced disease